GlassScriptPhysician profile
Ilyas M Memon
NPI 1992762033
$6,543.46
in general payments reported to CMS, 2019-2025
35 companies · $1,052 in 2025
The $1,052 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,025 · 2020: $259 · 2021: $548 · 2022: $1,058 · 2023: $1,113 · 2024: $1,488 · 2025: $1,052.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,631 · Education: $19.32 · Travel and Lodging: $3.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,630.89 |
| Education | $19.32 |
| Travel and Lodging | $3.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,926.72 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,217.56 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $806.54 | 2019-2025 | Stelara, Tremfya, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $537.87 | 2019-2023 | Plenvu, Xifaxan |
| Lilly USA, LLC | $217.33 | 2024-2025 | Omvoh |
| Pfizer INC. | $165.81 | 2024-2025 | |
| Gilead Sciences, INC. | $131.84 | 2019-2023 | |
| Csa Medical, INC | $124.45 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $120.93 | 2022 | |
| Janssen Scientific Affairs, LLC | $119.74 | 2022 | |
| Ferring Pharmaceuticals INC. | $111.41 | 2019-2023 | Rebyota |
| Anx Robotica Corp | $104.91 | 2024 | |
| Boston Scientific Corporation | $91.30 | 2019 | |
| Qol Medical, LLC | $77.19 | 2019-2022 | |
| Celltrion USA INC. | $75.97 | 2024-2025 | Vegzelma, Zymfentra |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $72.49 | 2023 | Avsola, Amjevita |
| Phathom Pharmaceuticals, INC. | $68.18 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $67.97 | 2019-2024 | Dificid |
| Romark Laboratories, Lc | $67.55 | 2019 | |
| Nestle Healthcare Nutrition INC. | $60.29 | 2021 | |
| Celgene Corporation | $55.83 | 2022-2024 | Zeposia |
| Shionogi INC | $51.05 | 2019 | |
| Ardelyx, INC. | $49.84 | 2024-2025 | Ibsrela |
| Redhill Biopharma INC. | $42.89 | 2020-2021 | |
| Intercept Pharmaceuticals, INC. | $28.94 | 2019 | |
| Shire North American Group INC | $21.04 | 2019 | |
| Conmed Corporation | $20.62 | 2025 | Conmed Dilation |
| Braintree Laboratories, INC. | $17.59 | 2020 | |
| Ironwood Pharmaceuticals, INC | $17.51 | 2021 | |
| Madrigal Pharmaceuticals | $16.38 | 2024 | Resmetirom |
| Vivus LLC | $15.87 | 2021 | |
| Aimmune Therapeutics, INC. | $14.09 | 2025 | Vowst |
| Cumberland Pharmaceuticals, INC. | $13.40 | 2019 | |
| Evoke Pharma, INC. | $12.36 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$56,121.38 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ilyas Memon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.